Do drugs offering only PFS maintain quality of life sufficiently from a patient’s perspective? Results from AVALPROFS (Assessing the ‘VALue’ to patients of PROgression Free Survival) study

PURPOSE: Trials of novel drugs used in advanced disease often show only progression-free survival or modest overall survival benefits. Hypothetical studies suggest that stabilisation of metastatic disease and/or symptom burden are worth treatment-related side effects. We examined this premise contem...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenkins, V., Farewell, V., May, S., Catt, S., Matthews, L., Shilling, V., Dickson, J., Simcock, R., Fallowfield, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182366/
https://www.ncbi.nlm.nih.gov/pubmed/29845422
http://dx.doi.org/10.1007/s00520-018-4273-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182366/
https://www.ncbi.nlm.nih.gov/pubmed/29845422
http://dx.doi.org/10.1007/s00520-018-4273-3

Ejemplares similares